<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36541788</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2165-0497</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>14</Day></PubDate></JournalIssue><Title>Microbiology spectrum</Title><ISOAbbreviation>Microbiol Spectr</ISOAbbreviation></Journal><ArticleTitle>Umifenovir Epigenetically Targets the <i>IL-10</i> Pathway in Therapy against Coxsackievirus B4 Infection.</ArticleTitle><Pagination><StartPage>e0424822</StartPage><MedlinePgn>e0424822</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e04248-22</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/spectrum.04248-22</ELocationID><Abstract><AbstractText>Umifenovir, a broad-spectrum nonnucleoside antiviral drug, has a promising efficacy against coxsackievirus B4 (CVB4) infection, but its mechanism remains unclear. CVB4 is a common human single-stranded RNA virus that belongs to the <i>Picornaviridae</i> family and the <i>Enterovirus</i> genus. <i>Enterovirus</i> can cause severe diseases, such as meningitis, myocarditis, pancreatitis, insulin-dependent diabetes, and several other diseases, in both adults and children. We have previously demonstrated the critical role of interleukin 10 (IL-10) in promoting CVB4 infection and the downregulation of IL-10 by umifenovir. To further explore the underlying mechanisms of umifenovir, we characterized the epigenetic regulation of IL-10 in <i>IL-10</i> knockout RAW264.7 cells and a BALB/c mouse splenocyte model. Mechanistically, we found that umifenovir inhibited CVB4-activated IL-10 by enhancing the methylation level of the repressive histones H3K9me3 and H3K27me3 while reducing the acetylation level of the activating histone H3K9ac in the promoter region of the <i>IL-10</i> gene. Furthermore, using a chromosome conformation capture approach, we discovered that CVB4 infection activated the <i>IL-10</i> gene by forming an intrachromosomal interaction between the <i>IL-10</i> gene promoter and an intronic enhancer of the downstream <i>MK2</i> (mitogen-activated protein kinase [MAPK]-activated protein kinase 2 [<i>MAPKAPK2</i>]) gene, a critical component of the p38-MAPK signaling pathway, which is required for <i>IL-10</i> gene expression. However, umifenovir treatment abolished this spatial conformation and chromatin interaction, thus reducing the continuous expression of IL-10 and subsequent CVB4 replication. In conclusion, this study reveals a novel epigenetic mechanism by which umifenovir controls CVB4 infections, thus laying a theoretical foundation for therapeutic use of umifenovir. <b>IMPORTANCE</b> Viral infections are major threats to human health because of their strong association with a variety of inflammation-related diseases, especially cancer. Many antiviral drugs are performing poorly in treating viral infections. This is probably due to the immunosuppressive effect of highly expressed IL-10, which is caused by viral infection. Umifenovir is a broad-spectrum antiviral drug. Our recent studies showed that umifenovir has a significant inhibitory effect on CVB4 infection and can reduce IL-10 expression caused by CVB4. However, another antiviral drug, rupintrivir, showed good antiviral activity but had no effect on the expression of IL-10. This suggests that the regulation of IL-10 expression is a key part of the antiviral mechanism of umifenovir. Therefore, due to the dual function of the inhibition of CVB4 replication and the regulation of immune antiviral pathway, the mechanism of umifenovir is of great value to study.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shilin</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8430-5095</Identifier><AffiliationInfo><Affiliation>Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, Cancer Center, First Hospital of Jilin University, Changchun, Jilin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Xiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, First Hospital of Jilin University, Changchun, Jilin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Sennan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Frontier Medical Science of Jilin University, Changchun, Jilin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, Cancer Center, First Hospital of Jilin University, Changchun, Jilin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Xue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, Cancer Center, First Hospital of Jilin University, Changchun, Jilin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yichen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, Cancer Center, First Hospital of Jilin University, Changchun, Jilin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Cong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, Cancer Center, First Hospital of Jilin University, Changchun, Jilin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hongrui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Frontier Medical Science of Jilin University, Changchun, Jilin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Jiuwei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, Cancer Center, First Hospital of Jilin University, Changchun, Jilin, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Microbiol Spectr</MedlineTA><NlmUniqueID>101634614</NlmUniqueID><ISSNLinking>2165-0497</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>130068-27-8</RegistryNumber><NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance></Chemical><Chemical><RegistryNumber>93M09WW4RU</RegistryNumber><NameOfSubstance UI="C086979">umifenovir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="Y">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044127" MajorTopicYN="N">Epigenesis, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016753" MajorTopicYN="Y">Interleukin-10</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="Y">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CVB4 infection</Keyword><Keyword MajorTopicYN="N">IL10</Keyword><Keyword MajorTopicYN="N">chromatin remodeling</Keyword><Keyword MajorTopicYN="N">epigenetics</Keyword><Keyword MajorTopicYN="N">histone modification</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>21</Day><Hour>9</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36541788</ArticleId><ArticleId IdType="pmc">PMC9927110</ArticleId><ArticleId IdType="doi">10.1128/spectrum.04248-22</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Virgin HW, Wherry EJ, Ahmed R. 2009. Redefining chronic viral infection. Cell 138:30–50. doi:10.1016/j.cell.2009.06.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2009.06.036</ArticleId><ArticleId IdType="pubmed">19596234</ArticleId></ArticleIdList></Reference><Reference><Citation>Franquet T, Franks TJ, Lee KS, Marchiori E, Mazzini S, Giménez A, Johkoh T, Cho J, Galvin JR. 2022. Human oncoviruses and thoracic tumors: understanding the imaging findings. Radiographics 42:644–660. doi:10.1148/rg.210157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/rg.210157</ArticleId><ArticleId IdType="pubmed">35363552</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J, Li D. 2018. Searching for human oncoviruses: histories, challenges, and opportunities. J Cell Biochem 119:4897–4906. doi:10.1002/jcb.26717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.26717</ArticleId><ArticleId IdType="pubmed">29377246</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Zhi C, Li H, Huang D, Fan Q, Cui J, Liang C. 2017. Umifenovir effectively inhibits IL-10 dependent persistent Coxsackie B4 virus infection. Antiviral Res 141:165–173. doi:10.1016/j.antiviral.2017.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.02.018</ArticleId><ArticleId IdType="pubmed">28263801</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269–271. doi:10.1038/s41422-020-0282-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0282-0</ArticleId><ArticleId IdType="pmc">PMC7054408</ArticleId><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzorno A, Padey B, Dubois J, Julien T, Traversier A, Dulière V, Brun P, Lina B, Rosa-Calatrava M, Terrier O. 2020. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. Antiviral Res 181:104878. doi:10.1016/j.antiviral.2020.104878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104878</ArticleId><ArticleId IdType="pmc">PMC7361110</ArticleId><ArticleId IdType="pubmed">32679055</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaising J, Polyak SJ, Pecheur EI. 2014. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res 107:84–94. doi:10.1016/j.antiviral.2014.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2014.04.006</ArticleId><ArticleId IdType="pmc">PMC7113885</ArticleId><ArticleId IdType="pubmed">24769245</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouyang W, O’Garra A. 2019. IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation. Immunity 50:871–891. doi:10.1016/j.immuni.2019.03.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.03.020</ArticleId><ArticleId IdType="pubmed">30995504</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Wong K, Ouyang W, Rutz S. 2019. Targeting IL-10 family cytokines for the treatment of human diseases. Cold Spring Harb Perspect Biol 11:a028548. doi:10.1101/cshperspect.a028548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a028548</ArticleId><ArticleId IdType="pmc">PMC6360861</ArticleId><ArticleId IdType="pubmed">29038121</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C. 2008. Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev 223:114–131. doi:10.1111/j.1600-065X.2008.00635.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2008.00635.x</ArticleId><ArticleId IdType="pubmed">18613832</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Z, Huang G, Gao T, Huang T, Zou M, Zou Y, Duan S. 2020. Epigenetic changes associated with interleukin-10. Front Immunol 11:1105. doi:10.3389/fimmu.2020.01105.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01105</ArticleId><ArticleId IdType="pmc">PMC7287023</ArticleId><ArticleId IdType="pubmed">32582189</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. 2009. An operational definition of epigenetics. Genes Dev 23:781–783. doi:10.1101/gad.1787609.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1787609</ArticleId><ArticleId IdType="pmc">PMC3959995</ArticleId><ArticleId IdType="pubmed">19339683</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Z, Liu Y. 2018. DNA methylation in human diseases. Genes Dis 5:1–8. doi:10.1016/j.gendis.2018.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gendis.2018.01.002</ArticleId><ArticleId IdType="pmc">PMC6147084</ArticleId><ArticleId IdType="pubmed">30258928</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman PM. 2016. Epigenetics and genetics of viral latency. Cell Host Microbe 19:619–628. doi:10.1016/j.chom.2016.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2016.04.008</ArticleId><ArticleId IdType="pmc">PMC5166714</ArticleId><ArticleId IdType="pubmed">27173930</ArticleId></ArticleIdList></Reference><Reference><Citation>Atlante S, Mongelli A, Barbi V, Martelli F, Farsetti A, Gaetano C. 2020. The epigenetic implication in coronavirus infection and therapy. Clin Epigenetics 12:156. doi:10.1186/s13148-020-00946-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13148-020-00946-x</ArticleId><ArticleId IdType="pmc">PMC7576975</ArticleId><ArticleId IdType="pubmed">33087172</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Q, Yang Z, Liu Y, Deng H, Xiao H, Shi L, He J. 2009. Antiviral activity of Arbidol against Coxsackie virus B5 in vitro and in vivo. Arch Virol 154:601–607. doi:10.1007/s00705-009-0346-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-009-0346-4</ArticleId><ArticleId IdType="pmc">PMC7086808</ArticleId><ArticleId IdType="pubmed">19291363</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei F, Li J-l, Ling J-x, Chen L-J, Li N, Liu Y-Y, Luo F, Xiong H-R, Hou W, Yang Z-Q. 2013. Establishment of SYBR green-based qPCR assay for rapid evaluation and quantification for anti-Hantaan virus compounds in vitro and in suckling mice. Virus Genes 46:54–62. doi:10.1007/s11262-012-0834-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11262-012-0834-6</ArticleId><ArticleId IdType="pubmed">23054436</ArticleId></ArticleIdList></Reference><Reference><Citation>Fediakina IT, Shchelkanov MI, Deriabin PG, Leneva IA, Gudova NV, Kondrat’eva TV, L’vov DK. 2011. Susceptibility of pandemic influenza virus A 2009 H1N1 and highly pathogenic avian influenza virus A H5N1 to antiinfluenza agents in cell culture. Antibiot Khimioter 56:3–9. (In Russian.)</Citation><ArticleIdList><ArticleId IdType="pubmed">21913403</ArticleId></ArticleIdList></Reference><Reference><Citation>Pécheur E-I, Lavillette D, Alcaras F, Molle J, Boriskin YS, Roberts M, Cosset FL, Polyak SJ. 2007. Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol. Biochemistry 46:6050–6059. doi:10.1021/bi700181j.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi700181j</ArticleId><ArticleId IdType="pmc">PMC2532706</ArticleId><ArticleId IdType="pubmed">17455911</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi L, Xiong H, He J, Deng H, Li Q, Zhong Q, Hou W, Cheng L, Xiao H, Yang Z. 2007. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch Virol 152:1447–1455. doi:10.1007/s00705-007-0974-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-007-0974-5</ArticleId><ArticleId IdType="pubmed">17497238</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaising J, Lévy PL, Polyak SJ, Stanifer M, Boulant S, Pécheur E-I. 2013. Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking. Antiviral Res 100:215–219. doi:10.1016/j.antiviral.2013.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2013.08.008</ArticleId><ArticleId IdType="pubmed">23981392</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MBA. 2006. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 12:1301–1309. doi:10.1038/nm1492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1492</ArticleId><ArticleId IdType="pmc">PMC2535582</ArticleId><ArticleId IdType="pubmed">17041596</ArticleId></ArticleIdList></Reference><Reference><Citation>Ejrnaes M, Filippi CM, Martinic MM, Ling EM, Togher LM, Crotty S, von Herrath MG. 2006. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 203:2461–2472. doi:10.1084/jem.20061462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20061462</ArticleId><ArticleId IdType="pmc">PMC2118120</ArticleId><ArticleId IdType="pubmed">17030951</ArticleId></ArticleIdList></Reference><Reference><Citation>Saraiva M, Vieira P, O’Garra A. 2020. Biology and therapeutic potential of interleukin-10. J Exp Med 217:e20190418. doi:10.1084/jem.20190418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20190418</ArticleId><ArticleId IdType="pmc">PMC7037253</ArticleId><ArticleId IdType="pubmed">31611251</ArticleId></ArticleIdList></Reference><Reference><Citation>Santarelli R, Gonnella R, Di Giovenale G, Cuomo L, Capobianchi A, Granato M, Gentile G, Faggioni A, Cirone M. 2015. STAT3 activation by KSHV correlates with IL-10, IL-6 and IL-23 release and an autophagic block in dendritic cells. Sci Rep 4:4241. doi:10.1038/srep04241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep04241</ArticleId><ArticleId IdType="pmc">PMC3937791</ArticleId><ArticleId IdType="pubmed">24577500</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Grol J, Subauste C, Andrade RM, Fujinaga K, Nelson J, Subauste CS. 2010. HIV-1 inhibits autophagy in bystander macrophage/monocytic cells through Src-Akt and STAT3. PLoS One 5:e11733. doi:10.1371/journal.pone.0011733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0011733</ArticleId><ArticleId IdType="pmc">PMC2908694</ArticleId><ArticleId IdType="pubmed">20661303</ArticleId></ArticleIdList></Reference><Reference><Citation>Couper KN, Blount DG, Riley EM. 2008. IL-10: the master regulator of immunity to infection. J Immunol 180:5771–5777. doi:10.4049/jimmunol.180.9.5771.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.180.9.5771</ArticleId><ArticleId IdType="pubmed">18424693</ArticleId></ArticleIdList></Reference><Reference><Citation>Maris CH, Chappell CP, Jacob J. 2007. Interleukin-10 plays an early role in generating virus-specific T cell anergy. BMC Immunol 8:8. doi:10.1186/1471-2172-8-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2172-8-8</ArticleId><ArticleId IdType="pmc">PMC1903364</ArticleId><ArticleId IdType="pubmed">17570849</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinic MM, von Herrath MG. 2008. Novel strategies to eliminate persistent viral infections. Trends Immunol 29:116–124. doi:10.1016/j.it.2007.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2007.12.002</ArticleId><ArticleId IdType="pubmed">18258483</ArticleId></ArticleIdList></Reference><Reference><Citation>Díaz-Valdés N, Manterola L, Belsúe V, Riezu-Boj JI, Larrea E, Echeverria I, Llópiz D, López-Sagaseta J, Lerat H, Pawlotsky JM, Prieto J, Lasarte JJ, Borrás-Cuesta F, Sarobe P. 2011. Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10. Hepatology 53:23–31. doi:10.1002/hep.23980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.23980</ArticleId><ArticleId IdType="pubmed">21154952</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobo-Silva D, Carriche GM, Castro AG, Roque S, Saraiva M. 2016. Balancing the immune response in the brain: IL-10 and its regulation. J Neuroinflammation 13:297. doi:10.1186/s12974-016-0763-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0763-8</ArticleId><ArticleId IdType="pmc">PMC5121946</ArticleId><ArticleId IdType="pubmed">27881137</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. 2011. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 29:71–109. doi:10.1146/annurev-immunol-031210-101312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-031210-101312</ArticleId><ArticleId IdType="pubmed">21166540</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CMT, Pryer N, Daniel D, Hwang ES, Rugo HS, Coussens LM. 2014. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26:623–637. doi:10.1016/j.ccell.2014.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2014.09.006</ArticleId><ArticleId IdType="pmc">PMC4254570</ArticleId><ArticleId IdType="pubmed">25446896</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, Liu C, Callahan DJ, Sun Z, Sun T, Tabib T, Pennathur A, Corry DB, Luketich JD, Lafyatis R, Chen W, Poholek AC, Bruno TC, Workman CJ, Vignali DAA. 2019. Adaptive plasticity of IL-10(+) and IL-35(+) Treg cells cooperatively promotes tumor T cell exhaustion. Nat Immunol 20:724–735. doi:10.1038/s41590-019-0346-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-019-0346-9</ArticleId><ArticleId IdType="pmc">PMC6531353</ArticleId><ArticleId IdType="pubmed">30936494</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna BS, Llaó-Cid L, Iskar M, Roessner PM, Klett LC, Wong JKL, Paul Y, Ioannou N, Öztürk S, Mack N, Kalter V, Colomer D, Campo E, Bloehdorn J, Stilgenbauer S, Dietrich S, Schmidt M, Gabriel R, Rippe K, Feuerer M, Ramsay AG, Lichter P, Zapatka M, Seiffert M. 2021. Interleukin-10 receptor signaling promotes the maintenance of a PD-1(int) TCF-1(+) CD8(+) T cell population that sustains anti-tumor immunity. Immunity 54:2825–2841.e10. doi:10.1016/j.immuni.2021.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.11.004</ArticleId><ArticleId IdType="pubmed">34879221</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan MAJ, Shilatifard A. 2020. Reevaluating the roles of histone-modifying enzymes and their associated chromatin modifications in transcriptional regulation. Nat Genet 52:1271–1281. doi:10.1038/s41588-020-00736-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-020-00736-4</ArticleId><ArticleId IdType="pubmed">33257899</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence M, Daujat S, Schneider R. 2016. Lateral thinking: how histone modifications regulate gene expression. Trends Genet 32:42–56. doi:10.1016/j.tig.2015.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tig.2015.10.007</ArticleId><ArticleId IdType="pubmed">26704082</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Shilatifard A. 2019. Epigenetic modifications of histones in cancer. Genome Biol 20:245. doi:10.1186/s13059-019-1870-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-019-1870-5</ArticleId><ArticleId IdType="pmc">PMC6868810</ArticleId><ArticleId IdType="pubmed">31747960</ArticleId></ArticleIdList></Reference><Reference><Citation>Chlamydas S, Papavassiliou AG, Piperi C. 2021. Epigenetic mechanisms regulating COVID-19 infection. Epigenetics 16:263–270. doi:10.1080/15592294.2020.1796896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15592294.2020.1796896</ArticleId><ArticleId IdType="pmc">PMC7901548</ArticleId><ArticleId IdType="pubmed">32686577</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirvaliloo M. 2021. Epigenomics in COVID-19; the link between DNA methylation, histone modifications and SARS-CoV-2 infection. Epigenomics 13:745–750. doi:10.2217/epi-2021-0057.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/epi-2021-0057</ArticleId><ArticleId IdType="pmc">PMC8074570</ArticleId><ArticleId IdType="pubmed">33876664</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai K, Cullen BR. 2020. Epigenetic and epitranscriptomic regulation of viral replication. Nat Rev Microbiol 18:559–570. doi:10.1038/s41579-020-0382-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-0382-3</ArticleId><ArticleId IdType="pmc">PMC7291935</ArticleId><ArticleId IdType="pubmed">32533130</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng F, Lienlaf M, Perez-Villarroel P, Wang H-W, Lee C, Woan K, Woods D, Knox T, Bergman J, Pinilla-Ibarz J, Kozikowski A, Seto E, Sotomayor EM, Villagra A. 2014. Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells. Mol Immunol 60:44–53. doi:10.1016/j.molimm.2014.02.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2014.02.019</ArticleId><ArticleId IdType="pmc">PMC4020151</ArticleId><ArticleId IdType="pubmed">24747960</ArticleId></ArticleIdList></Reference><Reference><Citation>Villagra A, Cheng F, Wang H-W, Suarez I, Glozak M, Maurin M, Nguyen D, Wright KL, Atadja PW, Bhalla K, Pinilla-Ibarz J, Seto E, Sotomayor EM. 2009. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 10:92–100. doi:10.1038/ni.1673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1673</ArticleId><ArticleId IdType="pmc">PMC3925685</ArticleId><ArticleId IdType="pubmed">19011628</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Ma J, Trinh RT, Heijnen CJ, Kavelaars A. 2022. An HDAC6 inhibitor reverses chemotherapy-induced mechanical hypersensitivity via an IL-10 and macrophage dependent pathway. Brain Behav Immun 100:287–296. doi:10.1016/j.bbi.2021.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.12.005</ArticleId><ArticleId IdType="pmc">PMC8766942</ArticleId><ArticleId IdType="pubmed">34915156</ArticleId></ArticleIdList></Reference><Reference><Citation>Holla S, Prakhar P, Singh V, Karnam A, Mukherjee T, Mahadik K, Parikh P, Singh A, Rajmani RS, Ramachandra SG, Balaji KN. 2016. MUSASHI-mediated expression of JMJD3, a H3K27me3 demethylase, is involved in foamy macrophage generation during mycobacterial infection. PLoS Pathog 12:e1005814. doi:10.1371/journal.ppat.1005814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005814</ArticleId><ArticleId IdType="pmc">PMC4988650</ArticleId><ArticleId IdType="pubmed">27532872</ArticleId></ArticleIdList></Reference><Reference><Citation>Cribbs A, Hookway ES, Wells G, Lindow M, Obad S, Oerum H, Prinjha RK, Athanasou N, Sowman A, Philpott M, Penn H, Soderstrom K, Feldmann M, Oppermann U. 2018. Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells. J Biol Chem 293:2422–2437. doi:10.1074/jbc.RA117.000698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA117.000698</ArticleId><ArticleId IdType="pmc">PMC5818173</ArticleId><ArticleId IdType="pubmed">29301935</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohmdorfer G, Wierzbicki AT. 2015. Control of chromatin structure by long noncoding RNA. Trends Cell Biol 25:623–632. doi:10.1016/j.tcb.2015.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2015.07.002</ArticleId><ArticleId IdType="pmc">PMC4584417</ArticleId><ArticleId IdType="pubmed">26410408</ArticleId></ArticleIdList></Reference><Reference><Citation>Fyodorov DV, Zhou B-R, Skoultchi AI, Bai Y. 2018. Emerging roles of linker histones in regulating chromatin structure and function. Nat Rev Mol Cell Biol 19:192–206. doi:10.1038/nrm.2017.94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm.2017.94</ArticleId><ArticleId IdType="pmc">PMC5897046</ArticleId><ArticleId IdType="pubmed">29018282</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha PP, Raviram R, Bonneau R, Skok JA. 2015. Breaking TADs: insights into hierarchical genome organization. Epigenomics 7:523–526. doi:10.2217/epi.15.25.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/epi.15.25</ArticleId><ArticleId IdType="pmc">PMC4624204</ArticleId><ArticleId IdType="pubmed">26111025</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon JR, Selvaraj S, Yue F, Kim A, Li Y, Shen Y, Hu M, Liu JS, Ren B. 2012. Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature 485:376–380. doi:10.1038/nature11082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11082</ArticleId><ArticleId IdType="pmc">PMC3356448</ArticleId><ArticleId IdType="pubmed">22495300</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L, Luo Y, Guo X, Liu S, Li S, Li J, Zhang Z, Zhao Y, Zhang Q, Gao F, Ji X, Gao X, Li Y, You F. 2022. SAFA facilitates chromatin opening of immune genes through interacting with anti-viral host RNAs. PLoS Pathog 18:e1010599. doi:10.1371/journal.ppat.1010599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010599</ArticleId><ArticleId IdType="pmc">PMC9200321</ArticleId><ArticleId IdType="pubmed">35658050</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlting C, Trilling M, Tiedje C, Le-Trilling VTK, Albrecht U, Kluge S, Zimmermann A, Graf D, Gaestel M, Hengel H, Häussinger D, Bode JG. 2016. MAPKAP kinase 2 regulates IL-10 expression and prevents formation of intrahepatic myeloid cell aggregates during cytomegalovirus infections. J Hepatol 64:380–389. doi:10.1016/j.jhep.2015.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2015.08.012</ArticleId><ArticleId IdType="pubmed">26299622</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Wang Y, Jia L, Wen X, Du Z, Wang C, Hao Y, Yu D, Zhou L, Chen N, Chen J, Chen H, Zhang H, Celik I, Gülsoy G, Luo J, Qin B, Cui X, Liu Z, Zhang S, Esteban MA, Ay F, Xu W, Chen R, Li W, Hoffman AR, Hu J-F, Cui J. 2019. Profiling the long noncoding RNA interaction network in the regulatory elements of target genes by chromatin in situ reverse transcription sequencing. Genome Res 29:1521–1532. doi:10.1101/gr.244996.118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.244996.118</ArticleId><ArticleId IdType="pmc">PMC6724666</ArticleId><ArticleId IdType="pubmed">31315906</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. Am J Epidemiol 27:493–497. doi:10.1093/oxfordjournals.aje.a118408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a118408</ArticleId></ArticleIdList></Reference><Reference><Citation>Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F. 2013. Multiplex genome engineering using CRISPR/Cas systems. Science 339:819–823. doi:10.1126/science.1231143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1231143</ArticleId><ArticleId IdType="pmc">PMC3795411</ArticleId><ArticleId IdType="pubmed">23287718</ArticleId></ArticleIdList></Reference><Reference><Citation>Harary I, Farley B. 1960. In vitro studies of single isolated beating heart cells. Science 131:1674–1675. doi:10.1126/science.131.3414.1674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.131.3414.1674</ArticleId><ArticleId IdType="pubmed">14399673</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida Y, Wang MQ, Liu JN, Shan BE, Yamashita U. 1997. Immunomodulating activity of Chinese medicinal herbs and Oldenlandia diffusa in particular. Int J Immunopharmacol 19:359–370. doi:10.1016/S0192-0561(97)00076-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0192-0561(97)00076-3</ArticleId><ArticleId IdType="pubmed">9568540</ArticleId></ArticleIdList></Reference><Reference><Citation>Chomczynski P, Sacchi N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159. doi:10.1016/0003-2697(87)90021-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0003-2697(87)90021-2</ArticleId><ArticleId IdType="pubmed">2440339</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Li W, Sun Y, Yu D, Wen X, Wang H, Cui J, Wang G, Hoffman AR, Hu J-F. 2014. A novel antisense long noncoding RNA within the IGF1R gene locus is imprinted in hematopoietic malignancies. Nucleic Acids Res 42:9588–9601. doi:10.1093/nar/gku549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku549</ArticleId><ArticleId IdType="pmc">PMC4150754</ArticleId><ArticleId IdType="pubmed">25092925</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>